REVIEW ARTICLEPotential role of targeted therapies in the treatment of triple-negative breast cancerJia, Lee Yueh; Shanmugam, Muthu K.; Sethi, Gautam; Bishayee, AnupamAuthor Information aDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore bSchool of Biomedical Sciences, CHIRI Biosciences Research Precinct, Curtin University, Perth, Western Australia, Australia cDepartment of Pharmaceutical Sciences, College of Pharmacy, Larkin Health Sciences Institute, Miami, Florida, USA Correspondence to Gautam Sethi, PhD, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore Tel: +65 651 63267; fax: +65 687 37690; e-mail: [email protected] Received September 8, 2015 Accepted November 28, 2015 Anti-Cancer Drugs: March 2016 - Volume 27 - Issue 3 - p 147-155 doi: 10.1097/CAD.0000000000000328 Buy Metrics Abstract Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen, progesterone, and the Her2/neu receptor and is usually diagnosed by immunohistochemistry. Mutations in the BRCA1 gene, as well as overexpression of oncogenic kinases, such as human epidermal growth factor receptor 2, vascular endothelial growth factor-A, insulin-like growth factor-1 (IGF-1)/IGF-1 receptor, and transforming growth factor-β1, have been found to be correlated with a higher risk of metastasis and poor overall survival in TNBC patients. The current review briefly discusses the various treatment options including chemotherapeutics and targeted therapies that are available currently for the therapy of TNBC patients and highlights their comparative benefits and disadvantages for clinical application. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.